The advent of the first anti-HER2 targeted agent, trastuzumab, remarkably improved the clinical outcomes of patients with HER2- positive breast cancer and at the same time contributed to the identification of HER2-positive breast cancer as a distinct biologic subtype [1, 2]. Here, ERBB2 is linked to breast cancer.